SCHEMBL4675705

SCHEMBL4675705

COc1ccccc1Cc1occc1C(=O)C=C(O)c1nc[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.39
CYP1A1 P04798 1/20 0.36
ABCB1 P08183 1/20 0.36
CYP1B1 Q16678 1/20 0.36
NR3C2 P08235 1/20 0.35
AR P10275 1/20 0.34
POLB P06746 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
RECQL P46063 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BRS3 P32247 1/20 0.34
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675787 0.86 ALDH1A1 (0.37) ALDH1A1CYP1A1ABCB1CYP1B1NR3C2
SCHEMBL4676607 0.86 LMNA (0.33) ALDH1A1LMNAPOLBSMN1; SMN2HTT
SCHEMBL4672929 0.86 NPC1 (0.36) NPC1ALDH1A1LMNANR3C2AR
SCHEMBL4677650 0.84 TP53 (0.35) NPC1ALDH1A1CYP1A1ABCB1CYP1B1
SCHEMBL4674056 0.83 GPR52 (0.35) NPC1ALDH1A1NR3C2ARSMN1; SMN2
SCHEMBL4679493 0.83 AR (0.37) LMNANR3C2ARPOLBSMN1; SMN2
SCHEMBL4676408 0.82 KDM4C (0.43) NPC1LMNANR3C2PKMRAB9A
SCHEMBL4673098 0.81 L3MBTL1 (0.39) ALDH1A1LMNACYP1A1ABCB1CYP1B1
SCHEMBL4674906 0.81 CYP1A1 (0.40) NPC1ALDH1A1LMNACYP1A1ABCB1
SCHEMBL4671571 0.81 TP53 (0.44) NPC1LMNACYP1A1ABCB1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPC1 934/4885ALDH1A1 980/4885LMNA 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.